Radionuclide Therapy of Bone Metastases with Radium-223 Chloride in Prostate Cancer Patients
Radionuclide Therapy of Bone Metastases with Radium-223 Chloride in Prostate Cancer Patients
复制标题
223氯化镭放射性核素治疗前列腺癌骨转移
DOI：
10.1007/978-3-030-39457-8_31
复制
发表时间：
2020
影响因子：
10.6
通讯作者：
H. Palmedo
中科院分区：
文献类型：
--
作者：
H. Palmedo
氯化镭 223 可以延长有症状的去势抵抗性前列腺癌患者的生存期并提高生活质量。应仅限于接受过两次全身二线治疗的无内脏转移（淋巴结转移除外）的患者。作为化疗前后的单一疗法，镭 223 具有良好的安全性。
Radium-223 chloride can prolong survival and improve quality of life in symptomatic, castration-resistant prostate cancer patients. It should be restricted to patients without visceral metastases (lymph node metastases excluded) having received two systemic second-line treatments. As a monotherapy before or after chemotherapy, radium-223 has a favourable safety profile.